FDA Reluctantly Grants Teva Exclusivity For Cozaar And Hyzaar Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency says it has no choice but to award Teva exclusivity given an appeals court decision limiting forfeiture; Apotex has not decided whether it will challenge the court's ruling.
You may also be interested in...
FDA In Tug-Of-War Over Generic Cozaar/Hyzaar: Apotex And Roxane Sue Agency To Block Teva's Marketing Exclusivity
FDA is engaged in a heated legal battle with Apotex and Roxane over its decision to grant Teva 180-day marketing exclusivity for generic versions of Merck's hypertension drugs Cozaar (losartan) and Hyzaar (losartan/hydrochlorothiazide)
FDA In Tug-Of-War Over Generic Cozaar/Hyzaar: Apotex And Roxane Sue Agency To Block Teva's Marketing Exclusivity
FDA is engaged in a heated legal battle with Apotex and Roxane over its decision to grant Teva 180-day marketing exclusivity for generic versions of Merck's hypertension drugs Cozaar (losartan) and Hyzaar (losartan/hydrochlorothiazide)
Teva's Exclusivity For Cozaar And Hyzaar Generics Imperiled Once Again
FDA tells court it is considering whether the fact that the patent has expired because Merck did not pay maintenance fees means that Teva could lose its 180-day prize.